OBJECTIVES: Anti-TNFs represent a substantial cost in the European healthcare systems. CT-P13, infliximab biosimilar product, has been already marketed in most European markets under two brand names for over a year with Flixabi^®, 2^nd infliximab biosimilar product, receiving European Commission approval in June 2016. However, biosimilar penetration varies significantly across different countries and substantial budget savings could still be potentially achieved. This study’s objective was to assess the budget impact of introducing Flixabi in 3 European countries for all licensed infliximab indications. METHODS: A budget-impact model was used to estimate the cost saving potential of introducing Flixabi in France, Italy & UK vs Remicade^®, the infliximab reference product, over three-year time horizon from payer’s perspective. Current Remicade-treated population has been estimated through sales data (GERS for France; IMS for Italy and UK), assuming constant population during the 3-year horizon. Patients already on the first two approved biosimilars were assumed to remain on these biosimilars. Four scenarios were developed with two Flixabi adoptions (slow uptake: 10%, 20%, 30% and rapid uptake: 20%, 40%, 60% at year 1, 2, 3 respectively) and with two discount prices for Flixabi vs. Remicade price (minimum and maximum discount given by the other two infliximab biosimilars in each country). Remicade prices were obtained from published sources and 5% price erosion per year was modelled for both products. RESULTS: Over the three-year horizon, Flixabi introduction in the biologic treatment setting resulted in projected budget-savings of: France: €41.5m-€103.7m, Italy: €9.3m-€31.4m, and UK: £19.8m-£66.0m for all scenarios. This would allow for savings equivalent of 19,641 to 69,983 patient-years in all three countries. CONCLUSIONS: The relatively slow uptake of infliximab biosimilars leaves substantial cost-saving opportunities for introduction of Flixabi in all studied countries. Flixabi will help leveraging the economic benefit of biosimilars in countries where the adoption of biosimilars has not yet been exploited.